{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:16:08Z","timestamp":1772165768722,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972371"],"award-info":[{"award-number":["81972371"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Songjiang District Medical and Health Science and Technology Research Project","award":["21SJKJGG97"],"award-info":[{"award-number":["21SJKJGG97"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15028-5","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:08:33Z","timestamp":1762344513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of prostate volume and nomograms for predicting recurrence in patients with non-muscle invasive bladder cancer: a multi-institutional study"],"prefix":"10.1186","volume":"25","author":[{"given":"Dichao","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunqiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiheng","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongchuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"15028_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"15028_CR2","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pi\u00f1eiro L, Gonzalez M, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195\u2013203. https:\/\/doi.org\/10.1016\/j.juro.2009.07.016.","journal-title":"J Urol"},{"key":"15028_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.urolonc.2024.12.264","volume":"43","author":"S Daneshmand","year":"2025","unstructured":"Daneshmand S, Kamat AM, Shore ND, Meeks JJ, Galsky MD, Jacob JM, et al. Development of TAR-200: a novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer. Urologic Oncology: Seminars Original Investigations. 2025;43:286\u201396. https:\/\/doi.org\/10.1016\/j.urolonc.2024.12.264.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"15028_CR4","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s11255-023-03867-9","volume":"56","author":"IJ Beijert","year":"2023","unstructured":"Beijert IJ, Hentschel AE, Br\u00fcndl J, Comp\u00e9rat EM, Plass K, Rodr\u00edguez O, et al. Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis? Int Urol Nephrol. 2023;56:1323\u201333. https:\/\/doi.org\/10.1007\/s11255-023-03867-9.","journal-title":"Int Urol Nephrol"},{"key":"15028_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234\u201341. https:\/\/doi.org\/10.1016\/j.eururo.2012.07.033.","journal-title":"Eur Urol"},{"key":"15028_CR6","first-page":"157","volume":"21","author":"M Mansoor","year":"2011","unstructured":"Mansoor M, Ali S, Fasihuddin Q, Baloch MU. Superficial bladder tumours: recurrence and progression. J Coll Physicians Surg Pak. 2011;21:157\u201360.","journal-title":"J Coll Physicians Surg Pak"},{"key":"15028_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.7326\/M23-0113","volume":"176","author":"GW Smetana","year":"2023","unstructured":"Smetana GW, Smith CC, Singla A, Libman H. How would you manage this patient with benign prostatic hyperplasia?? Grand rounds discussion from Beth Israel Deaconess Medical Center. Ann Intern Med. 2023;176:545\u201355. https:\/\/doi.org\/10.7326\/M23-0113.","journal-title":"Ann Intern Med"},{"key":"15028_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00345-018-2216-8","volume":"36","author":"C-W Fang","year":"2018","unstructured":"Fang C-W, Liao C-H, Wu S-C, Muo C-H. Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study. World J Urol. 2018;36:931\u20138. https:\/\/doi.org\/10.1007\/s00345-018-2216-8.","journal-title":"World J Urol"},{"key":"15028_CR9","doi-asserted-by":"publisher","first-page":"e3493","DOI":"10.1097\/MD.0000000000003493","volume":"95","author":"X Dai","year":"2016","unstructured":"Dai X, Fang X, Ma Y, Xianyu J. Benign prostatic hyperplasia and the risk of prostate cancer and bladder cancer: a meta-analysis of observational studies. Medicine (Baltimore). 2016;95:e3493. https:\/\/doi.org\/10.1097\/MD.0000000000003493.","journal-title":"Medicine (Baltimore)"},{"key":"15028_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1016696","volume":"13","author":"W Du","year":"2022","unstructured":"Du W, Wang T, Zhang W, Xiao Y, Wang X. Genetically supported causality between benign prostate hyperplasia and urinary bladder neoplasms: a Mendelian randomization study. Front Genet. 2022;13:1016696. https:\/\/doi.org\/10.3389\/fgene.2022.1016696.","journal-title":"Front Genet"},{"key":"15028_CR11","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.juro.2016.08.006","volume":"197","author":"M Shiota","year":"2017","unstructured":"Shiota M, Kiyoshima K, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, et al. Suppressed recurrent bladder cancer after androgen suppression with androgen deprivation therapy or 5\u03b1-reductase inhibitor. J Urol. 2017;197:308\u201313. https:\/\/doi.org\/10.1016\/j.juro.2016.08.006.","journal-title":"J Urol"},{"key":"15028_CR12","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1111\/j.1464-410X.2012.11107.x","volume":"110","author":"K Axcrona","year":"2012","unstructured":"Axcrona K, Aaltomaa S, Da Silva CM, \u00d6zen H, Damber J, Tank\u00f3 LB, et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int. 2012;110:1721\u20138. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11107.x.","journal-title":"BJU Int"},{"key":"15028_CR13","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtr\u00f6der K, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12:2301. https:\/\/doi.org\/10.1038\/s41467-021-22465-w.","journal-title":"Nat Commun"},{"key":"15028_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12894-023-01342-2","volume":"23","author":"H Wan","year":"2023","unstructured":"Wan H, Zhan X, Li X, Chen T, Deng X, Liu Y, et al. Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer. BMC Urol. 2023;23:182. https:\/\/doi.org\/10.1186\/s12894-023-01342-2.","journal-title":"BMC Urol"},{"key":"15028_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","volume":"5","author":"WS Tan","year":"2022","unstructured":"Tan WS, Steinberg G, Witjes JA, Li R, Shariat SF, Roupret M, et al. Intermediate-risk non\u2013muscle-invasive bladder cancer: updated consensus definition and management recommendations from the international bladder cancer group. Eur Urol Oncol. 2022;5:505\u201316. https:\/\/doi.org\/10.1016\/j.euo.2022.05.005.","journal-title":"Eur Urol Oncol"},{"key":"15028_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.euo.2023.01.004","volume":"6","author":"IJ Beijert","year":"2023","unstructured":"Beijert IJ, Hentschel AE, Br\u00fcndl J, Comp\u00e9rat EM, Plass K, Rodr\u00edguez O, et al. Prognosis of primary papillary Ta grade 3 bladder cancer in the non\u2013muscle-invasive spectrum. Eur Urol Oncol. 2023;6:214\u201321. https:\/\/doi.org\/10.1016\/j.euo.2023.01.004.","journal-title":"Eur Urol Oncol"},{"key":"15028_CR17","doi-asserted-by":"publisher","unstructured":"Ferro M, Tataru OS, Fallara G, Fiori C, Manfredi M, Claps F, et al. Assessing the influence of smoking on inflammatory markers in Bacillus calmette Gu\u00e9rin response among bladder cancer patients: a novel machine-learning approach. Minerva Urol Nephrol. 2025;77. https:\/\/doi.org\/10.23736\/S2724-6051.24.05876-2.","DOI":"10.23736\/S2724-6051.24.05876-2"},{"key":"15028_CR18","doi-asserted-by":"publisher","first-page":"189e1","DOI":"10.1016\/j.urolonc.2024.11.015","volume":"43","author":"R Contieri","year":"2025","unstructured":"Contieri R, Claps F, Hurle R, Buffi NM, Lughezzani G, Lazzeri M, et al. Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy. Urologic Oncology: Seminars Original Investigations. 2025;43:189e1. https:\/\/doi.org\/10.1016\/j.urolonc.2024.11.015.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"15028_CR19","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1080\/13685538.2020.1718637","volume":"23","author":"L Zhou","year":"2020","unstructured":"Zhou L, Liang X, Zhang K. Assessment of the clinical efficacy of simultaneous transurethral resection of both bladder cancer and the prostate: a systematic review and meta-analysis. Aging Male. 2020;23:1182\u201393. https:\/\/doi.org\/10.1080\/13685538.2020.1718637.","journal-title":"Aging Male"},{"key":"15028_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.eururo.2024.04.031","volume":"86","author":"M Creta","year":"2024","unstructured":"Creta M, Russo GI, Bhojani N, Drake MJ, Gratzke C, Peyronnet B, et al. Bladder outlet obstruction relief and symptom improvement following medical and surgical therapies for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review. Eur Urol. 2024;86:315\u201326. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.031.","journal-title":"Eur Urol"},{"key":"15028_CR21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1186\/s12967-024-05604-x","volume":"22","author":"Z Song","year":"2024","unstructured":"Song Z, Cheng ZJ, Yuan H, Chang Z, Lv Y, Huang X, et al. Correlation between benign prostatic hyperplasia and comorbidities: a systematic analysis integrating global burden of disease and Mendelian randomization study. J Transl Med. 2024;22:1035. https:\/\/doi.org\/10.1186\/s12967-024-05604-x.","journal-title":"J Transl Med"},{"key":"15028_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184263","volume":"10","author":"J Lee","year":"2021","unstructured":"Lee J, Choo MS, Yoo S, Cho MC, Son H, Jeong H. Intravesical prostatic protrusion and prognosis of non-muscle invasive bladder cancer: analysis of long-term data over 5 years with machine-learning algorithms. J Clin Med. 2021;10:4263. https:\/\/doi.org\/10.3390\/jcm10184263.","journal-title":"J Clin Med"},{"key":"15028_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.04.008","volume":"84","author":"S Gravas","year":"2023","unstructured":"Gravas S, Gacci M, Gratzke C, Herrmann TRW, Karavitakis M, Kyriazis I, et al. Summary paper on the 2023 European association of urology guidelines on the management of non-neurogenic male lower urinary tract symptoms. Eur Urol. 2023;84:207\u201322. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.008.","journal-title":"Eur Urol"},{"key":"15028_CR24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/carcin\/23.6.907","volume":"23","author":"SS Hecht","year":"2002","unstructured":"Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis. 2002;23:907\u201322. https:\/\/doi.org\/10.1093\/carcin\/23.6.907.","journal-title":"Carcinogenesis"},{"key":"15028_CR25","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00428-015-1820-x","volume":"467","author":"G Nesi","year":"2015","unstructured":"Nesi G, Nobili S, Cai T, Caini S, Santi R. Chronic inflammation in urothelial bladder cancer. Virchows Arch. 2015;467:623\u201333. https:\/\/doi.org\/10.1007\/s00428-015-1820-x.","journal-title":"Virchows Arch"},{"key":"15028_CR26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/CU9.0000000000000218","volume":"17","author":"D Wang","year":"2023","unstructured":"Wang D, Ning H, Wu H, Song Y, Chu Y, Liu F, et al. Construction and evaluation of a novel prognostic risk model of aging-related genes in bladder cancer. Curr Urol. 2023;17:236\u201345. https:\/\/doi.org\/10.1097\/CU9.0000000000000218.","journal-title":"Curr Urol"},{"key":"15028_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.eururo.2015.01.032","volume":"68","author":"LA Kluth","year":"2015","unstructured":"Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, et al. Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature. Eur Urol. 2015;68:238\u201353. https:\/\/doi.org\/10.1016\/j.eururo.2015.01.032.","journal-title":"Eur Urol"},{"key":"15028_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10147-010-0049-6","volume":"15","author":"T Yamada","year":"2010","unstructured":"Yamada T, Tsuchiya K, Kato S, Kamei S, Taniguchi M, Takeuchi T, et al. A pretreatment nomogram predicting recurrence- and progression-free survival for nonmuscle invasive bladder cancer in Japanese patients. Int J Clin Oncol. 2010;15:271\u20139. https:\/\/doi.org\/10.1007\/s10147-010-0049-6.","journal-title":"Int J Clin Oncol"},{"key":"15028_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.eururo.2025.05.005","volume":"88","author":"JD Subiela","year":"2025","unstructured":"Subiela JD, Scilipoti P, Contieri R, Lobo N, Pichler R, Kamat AM. Management dilemma for very High-risk Non\u2013muscle-invasive bladder cancer: Real-World data challenge the guideline recommendation for upfront radical cystectomy. Eur Urol. 2025;88:228\u201330. https:\/\/doi.org\/10.1016\/j.eururo.2025.05.005.","journal-title":"Eur Urol"},{"key":"15028_CR30","doi-asserted-by":"publisher","unstructured":"Gudj\u00f3nsson S, Bl\u00e4ckberg M, Chebil G, Jahnson S, Olsson H, Bendahl P, et al. The value of bladder mapping and prostatic urethra biopsies for detection of carcinoma in situ (CIS). BJU Int. 2012;110. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10654.x.","DOI":"10.1111\/j.1464-410X.2011.10654.x"},{"key":"15028_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16828","author":"M Ferro","year":"2025","unstructured":"Ferro M, Catellani M, Bianchi R, Fallara G, Tozzi M, Maggi M, et al. Enhanced prognostic value of four-tier hybrid grading system in Ta non\u2010muscle\u2010invasive bladder cancer. BJU Int. 2025. https:\/\/doi.org\/10.1111\/bju.16828. :bju.16828.","journal-title":"BJU Int"},{"key":"15028_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.eururo.2024.08.013","volume":"86","author":"IJ Beijert","year":"2024","unstructured":"Beijert IJ, Hagberg O, G\u00e5rdmark T, Holmberg L, H\u00e4ggstr\u00f6m C, Johnston A, et al. The importance of being grade 3: a plea for a three-tier hybrid classification system for grade in primary non\u2013muscle-invasive bladder cancer. Eur Urol. 2024;86:391\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2024.08.013.","journal-title":"Eur Urol"},{"key":"15028_CR33","doi-asserted-by":"publisher","unstructured":"Contieri R, Martini A, Beijert IJ, Mertens LS, Hentschel AE, Br\u00fcndl J, et al. Towards defining Follow-up strategies for patients with primary Intermediate-risk Non\u2013muscle-invasive bladder cancer. Eur Urol Oncol. 2025;S258893112500104X. https:\/\/doi.org\/10.1016\/j.euo.2025.04.010.","DOI":"10.1016\/j.euo.2025.04.010"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15028-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:08:34Z","timestamp":1762344514000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15028-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15028"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15028-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4728588\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Shanghai General Hospital Institutional Review Board (20240909073949417).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to the publication of this work and have reviewed the manuscript prior to submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1719"}}